RxDoctor Payments Data

Michael James, MD

Internal Medicine · Raleigh, NCNPI 1538161609

Payments from drug & device makers

$54,647in general payments, 2019–2025

Across 288 payments — averaging $189.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • C. R. Bard, Inc. & Subsidiaries$50K
  • Novo Nordisk$416
  • Lilly USA, LLC$294
  • AstraZeneca$290
  • Boehringer Ingelheim$287
  • Amgen$271
  • plus $3K from 39 others

What the payments were for

  • Speaking & faculty fees$170%
  • Food & beverage$4,348100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$54,647 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$202,457
Medicare patients
572
Services billed
2,225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,079$495,560
JardianceEmpagliflozin251$174,501
OzempicSemaglutide96$99,890
XareltoRivaroxaban212$89,941
OtezlaApremilast26$52,863
NuplazidPimavanserin Tartrate18$42,117
MyrbetriqMirabegron188$41,402
TradjentaLinagliptin94$36,477
JanuviaSitagliptin Phosphate52$27,382
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$26,924
MounjaroTirzepatide24$25,204
ProliaDenosumab14$24,035
Breo ElliptaFluticasone/Vilanterol45$21,780
LinzessLinaclotide25$20,826
EntrestoSacubitril/Valsartan58$20,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$190$508,7551,121 claims
Boehringer IngelheimJardiance, Tradjenta$287$210,979345 claims
Novo NordiskOzempic$416$99,89096 claims
Johnson & JohnsonXarelto$198$89,941212 claims
AmgenOtezla, Prolia$271$76,89840 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$50$66,059127 claims
MerckJanuvia, Lagevrio (Eua)$104$43,87974 claims
Acadia Pharmaceuticals IncNuplazid$35$42,11718 claims
AbbVieLinzess, Restasis, Creon$136$40,42857 claims
AstraZenecaFarxiga, Symbicort$290$28,94765 claims
Lilly USA, LLCMounjaro$294$25,20424 claims
NovartisEntresto$252$20,14558 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →